An observational study in Hemorrhage and Vein Thrombosis, sponsored by G. d'Annunzio University. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-08.
Sponsored by G. d'Annunzio University · Observational
Patients with cancer hospitalized for an acute medical illness have an increased risk of venous thromboembolic events. Although international guidelines suggest the use of thromboprophylaxis in these patients, the recommendations are based on studies which included a percentage of patients with cancer without primarily focusing on this high risk group.
Since patients with cancer present an increased risk of bleeding complications it is critical to evaluate the safety of thromboprophylaxis in the cancer group. Recent studies suggest a limited use of thromboprophylaxis in these patients.
The aim of this study is to evaluate the use, efficacy and safety of thromboprophylaxis in medical cancer patients hospitalized for an acute medical disease.
Design: observational, prospective study Primary end-point: incidence of major and clinically relevant non major bleeding during hospitalization Secondary endpoints: frequency of use, doses and contraindications for pharmacological thromboprophylaxis; venous thromboembolic events up to three months after discharge
1,506 studies on the registry are indexed under Thrombosis; 238 are open to participants now.
This study's enrollment of 330 is above the median of 213 across 586 observational studies indexed under Thrombosis.
Browse Thrombosis studies →G. d'Annunzio University is the lead sponsor of 62 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with cancer hospitalized for an acute medical illness
Exclusion Criteria:
Major bleeding and clinically relevant non major bleeding
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Venous thromboembolism
Time frame: Participants will be followed up to 3 months after discharge, an expected average of 13 weeks
Minor bleeding
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
G. d'Annunzio University